Amortization expense for each of the three month periods ended November 30, 2017 and 2016 was $89,375 and $36,875, respectively.
Amortization expense for each of the three-month periods ended November 30, 2017 and 2016 was $150,000.
Amortization expense for each of the three-month periods ended November 30, 2017 and 2016 was $1,875.
Amortization expense for the three months ended November 30, 2017 was $79,176 and is included in cost of revenues.
Amortization of software development costs amounted to $285,310 and $284,217 for the three months ended November 30, 2017 and 2016, respectively.
On June 1, 2017, as part of the acquisition of DILIsym Services, Inc. the Company acquired certain developed technologies associated with the drug induced liver disease (DILI).
Prior to this lease DILIsym was on a month-to-month rental.
Total amortization expense for intellectual property agreements for the three months ended November 30, 2017 and 2016 was $320,417 and $188,750, respectively.
Three customers accounted for 9%, 7% (a dealer account in Japan representing various customers), and 6% of net sales during the three months ended November 30, 2016.Foreign currency exchange accounted for $47,000, the change mainly due to the yen strengthening in relation to the US dollar.
Overall gross margin remained fairly constant increasing by 0.1% to 75.4% in 1QFY18 from 75.3.9% in 1QFY17.
Cost of Revenues as a percentage of revenue remained fairly constant decreasing by 0.1% in 1QFY18 to 24.6% as compared to 24.7% in 1QFY17.
The Board of Directors must approve each quarterly dividend distribution and may decide to increase, decrease, or eliminate dividend distributions at any time.
In its data-mining role, MedChem Studio facilitates searching large chemical libraries to find molecules that contain identified substructures, and it enables rapid identification of clusters (classes) of molecules that share common substructures.
We continue to receive positive feedback about the functionality implemented in KIWI and the value of the approach we have taken to harness cloud technology.
In addition, we actively seek strategic acquisitions to expand the pharmaceutical software and services business and to explore opportunities in aerospace and general healthcare.
Already the most widely used program in the world for physiologically based pharmacokinetics (PBPK), the addition of these new capabilities is expected to expand the user base in the early pharmaceutical research and development process, while also helping us further penetrate the biopharmaceuticals, food, cosmetics, and general toxicology markets.
To ensure high-quality analyses, organizations must not only apply high-quality science, but must also be able to support the science by being able to validate the results.